Business
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nDr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders.\n\n\n\nDr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO).\n\n\n\nDr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications.\n\n\n\nDr. Grossman will succeed Dr. Hepner, who is transitioning his position due to personal reasons, but will remain committed to Coya as Clinical and Strategic Advisor.\n\n\n\n \n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer.\n\n\nDr. Grossman will succeed Dr. Adrian Hepner in this role, effective July 17th, 2023, and will leverage his over two decades of clinical development expertise to guide and oversee all of Coya’s development programs, including its lead asset, COYA 302, for the treatment of Amyotrophic Lateral Sclerosis (ALS).\n\n\nPrior to joining Coya, Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He also served as President and Chief Medical Officer at Glenmark Pharmaceuticals, (BSE: 532296), a $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next-generation biologics (including bi-specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.\n\n\n“We are grateful for Dr. Hepner’s leadership and ex...